[
  {
    "objectID": "evidence_tables.html#key-question-5",
    "href": "evidence_tables.html#key-question-5",
    "title": "Evidence Tables",
    "section": "Key Question 5",
    "text": "Key Question 5\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Sauer 2014\n\n737\nInclude: Age >18 yrs; undergoing cardiopulmonary bypass.Exclude: Emergency surgery; scheduled for an off-pump technique; patients with a life expectancy of <6months.\n\nThe intraoperative admin of dexamethasone did not reduce the incidence or duration of delirium in the first 4 days after cardiac surgery.\nA substudy of DECS trial\n    Ottens 2014\n\n291\nInclude: Age > 18 yrs;.Exclude: Vision impairments; hearing or motor impairment; mental illness.\n\nAt 1-month follow-up, 13.6% in the dexamethasone group 7.2% in the placebo group were diagnosed with POCD (relative risk, 1.87; 95% CI, 0.90 to 3.88; P = 0.09). At 12-month follow-up, 7.0% in the dexamethasone group and 3.5% in the placebo group had POCD (relative risk, 1.98; 95% CI, 0.61 to 6.40; P = 0.24).\n\n    Whitlock 2015\n\n7507\nInclude: Age >=18; EuroSCORE >=6 (Jul 2011, China and India included EuroSCORE>=4); cardiac surgery requiring cardiopulmonary bypass.Exclude:  Not specified.\n\nDifferences were not detected in 30-day mortality between patients receiving methylprednisolone (154/3755, 4%) compared with patients receiving placebo (177/3752, 5%), (RR, 95% CI: 0.87, 0.70-1.07). Differences were not detected in delirium by day 3 between patients receiving methylprednisolone (295/3755, 8%) compared with patients receiving placebo (289/3752, 8%), (RR, 95% CI: 1.02, 0.87-1.19).\n\n    Mansouri 2019\n\n150\nInclude: > 65 years of age; ASA I and II characteristics; No history of sensitivity to anesthetics; No history of moderate to severe mental disorders;.Exclude: Occurrence of severe hemodynamic disorder during the surgery leading to a change in anesthesia; extended surgery duration for >1 hour; Sensitivity to the anesthetics.\n\nNo statistically significant difference between the midazolam and dexmedetomidine groups in the MMSE score 24 hours after surgery (14% vs 12%, respectively) and 1 week postop (8% vs 12%, respectively; P > 0.05). However, there was a significant difference between these two groups and the control  (8% for Midazolam, 12% for Dexmedetomidine vs 20% Control; P < 0.05).\n\n    Yu 2017\n\n92\nInclude: Age >60 yrs; ASA I-II.Exclude: Senile dementia; coronary heart disease; hypertension; severe hepatic and renal dysfunction; other disease.\n\nPostoperative delirium occurrence rate of 6.52% in dexmedetomidine group was significantly lower than that in the control group, and the difference between the two groups had statistical significance (p <0.05).\n\n    Šakić 2015\n\n60\nInclude: Elderly patients with well-defined fracture femur for surgical procedure in spinal anesthesia (they never define the age criteria).Exclude: Diagnosis of diabetes mellitus, diagnosis of an autoimmune disease, corticosteroid and immunosuppressive use.\n\nDexamethasone group had less patients develop postoperative cognitive impairment compared to the levobupivacaine group, (17% vs 72%, respectively).\n\n    Mardani 2013\n\n110\nInclude: Did not specify.Exclude: Illiteracy; prolonged intubation; >3hrs of CPB; >80 yrs; EF lower than 20% hemodynamic instability; hx of delirium; Emergency Operation; >24hr intubation postoperatively.\n\nDelirium and hospital length of stay significantly decreased in the dexamethasone group compared to the placebo in the first postoperative day (4(9.3%) vs. 13 (26%), p=0.03; 12.93 ± 1.03 vs 13.64 ± 1.75 days, p=0.02, respectively).\n\n    Hongyu 2019\n\n90\nInclude: Age 65-80 years; tumor grade I-III; BMI 18.5-23.9; lung cancer.Exclude: Patients with glaucoma, cataract and other eye diseases; patients with central nervous system and psychiatric disorders, linguistically ineffective communication with psychologists; mini-mental state examination (MMSE) scores ≤23 points.\n\nMean MMSE score in elderly patients given penehyclidine hydrochloride was higher on POD 1 (24.7 vs 23.8; p<0.05) and lower POD 4 compared to controls (16.7 vs 23.5; p<0.001). Postoperative delirium was seen in 10% of PHH patients on POD 1 and 26.7% on POD 4 compared to 13.3% in controls.\n\n    Wang 2020\n\n44\nInclude: Currently using a nasal tracheal duct in ICU postop; required sedative treatment; age >= 18; ASA I or II.Exclude: Dx liver dysfunction; dx of kidney dysfunction; ALT exceeding 3x the upper limit of normal as indicator of liver damage; Serum creatinine and urea nitrogen exceeding the upper limit of normal as indicator of impaired renal function; acute myocardial infarction or severe heart failure; drug dependence; alcoholism' hx of psychological illness; severe cognitive dysfunction; currently pregnant or lactating; allergic to midazolam; allergic to dexmedetomidine.\n\nThe incidence of delirium in the dexmedetomidine group was significantly lower than in the midazolam group (1 (1.5%) vs 9 (45%), respectively; P=0.003).\nAuthors were emailed to inquire what scale was used to measure delirium.\n    Dieleman 2012\n\n4494\nInclude: Age > 18 yrs.Exclude: Emergent or off-pump procedure; life expectancy < 6 mo.\n\nPostoperative delirium was seen in 9.2% dexamethasone group and 11.7% in the placebo group (RR 0.79, 95% CI: 0.66-0.94, p=0.006).\nLarge multicenter clinical trial on dexamethasone. There were two substudies from this trial (Sauer 2014 and Ottens 2014) that focused on delirium and cognitive decline.\n    Hollinger 2021\n\n200\nInclude: Aged ≥65 years and scheduled for visceral, orthopaedic, vascular, gynaecological, cardiac, or thoracic surgery.Exclude: Delirium at admission; MMSE score < 24; DOS >= 3; dementia; known ICU admission; haloperidol or ketamine intolerance; communication issues; QT interval prolongation; Parkinson's disease; epilepsy; body weight > 100 kg; intake of dopaminergic drugs.\n\nDelirium was seen in 6.4% of patients in the ketamine group, 11.1% with haloperidol, and 9.1 % with placebo (p=0.16).\nBaden PRIDe Trial was an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial. The purpose of this study was to identify within a cohort of ICU patients admitted for severe illness those who are at risk of death in the year following the discharge from ICU. Eleven other articles have indexed this trial.\n    Glumac 2017\n\n169\nInclude: Patients age 41-84 years; elective coronary artery bypass graft, heart valve, or combined surgery with or without cardiopulmonary bypass.Exclude: Cerebrovascular incident past 3 yrs; mental illness; visual, hearing, or motor impairment interfering with cognitive assessment; left ventricular ejection fraction <35%; adrenal gland disease requiring steroids >7 days in past yr; alcohol (>50 g/day or >500 g/wk) or substance abuse; MMSE <26; BDI-II >19; preop CRP >5 mg/L; preop WBC <4 or >10 x10(ninth)/L; stroke; additional corticosteroid during study period.\n\nPatients undergoing cardiac surgery who received dexamethasone (n=80) experienced less postoperative cognitive decline compared with patients who received placebo (n=81), RR (95% CI): 0.43 (0.21-0.89). Subgroup analysis by age shows patients >=65 experience less cognitive decline when receiving dexamethasone (RR, 95% CI: 0.22, 0.05-0.94), while no difference is detected among patients <65 (RR, 95% CI: 0.59, 0.26-1.36).\n\n    Royse 2017\n\n555\nInclude: Enrolled in SIRS (Whitlock 2015): age >=18 years; EuroSCORE >=6; cardiac surgery requiring cardiopulmonary bypass.Exclude: Known cognitive impairment or psychiatric illness; (from Whitlock 2015: taking or expected to take steroids immediately postop; bacterial or fungal infection preceding 30 days; steroid intolerance or allergy; expected to receive aprotonin).\n\nIn a substudy of patients undergoing cardiac surgery requiring cardiopulmonary bypass, a difference was not detected in overall recovery at 6 months in patients receiving methylprednisolone compared with patients receiving placebo, odds ratios over time 039 to 1.45 (95% CI, 0.08-2.04 to 0.40-5.27). Differences were not detected in the subcategories of the recovery scale (cognitive, anxiety and depression, activities of daily living) between the study groups.\n\n    Hakim 2012\n\n101\nInclude: Age > 65 yrs.Exclude: Hx of neuropsychiatric disorders, alcoholism; intake of psychotropic mediations.\n\nIncidence of postoperative delirium was lower in the risperidone group compared to placebo (13.7% vs 34%, p=0.031) when given post-operatively.\n\n    Sultan 2010\n\n222\nInclude: Age > 65 yrs; ASA I-III.Exclude: Dementia; alcohol abuse; blind/deaf; severe infection; severe anemia; stroke; fluid or electrolyte imbalance; acute cardiac event; acute pulmonary events; on anticonvulsants, antidepressants, antihistamines, antiparkinsonians, antipsychotics, benzodiazepines.\n\nPostoperative delirium was seen in 9.4% of patients given melatonin compared to 32.6% in the control group. This study also compared patients given midazolam (44%) and clonidine (37.2%) preoperatively.\n\n    Zhu 2018\n\n178\nInclude: Patients age 65-75 years; elective total knee arthroplasty under general anesthesia.Exclude: MMSE <23; peptic ulcer disease; cardiac-cerebral vascular disease; chronic obstructive pulmonary disease; neurological or psychiatric disorders; NSAIDS allergy; drug or alcohol abuse; hepatic and/or kidney dysfunction; BMI >35; inability to communicate.\n\nIn patients undergoing total knee arthroplasty, at 7 days follow-up, 10/81 (12.3%) patients receiving celecoxib (200 mg, twice daily, 7 days preop) experienced postoperative cognitive dysfunction compared with 28/82 (34.1%) patients receiving placebo.\n\n    Zhou 2019\n\n180\nInclude: Patients age >70 years; ASA status I-II; hip arthroplasty surgery.Exclude: History of gastric ulcer or duodenal ulcer; flurbiprofen allergy; severe hepatic or renal disorders; ischemic heart disease; general or local infections.\n\nAmong patients undergoing hip arthroplasty surgery, patients receiving 50 mg flurbiprofen preoperatively (n=60) experienced higher MMSE scores compared with patients receiving nothing (n=60, p<0.01) and patients receiving 50 mg flurbiprofen intraoperatively (n=60, p<0.05) at 3, 12, and 24 h postsurgery. Patients receiving flurbiprofen intraoperatively experienced higher MMSE scores compared to patients receiving nothing, p<0.05.\n\n    Larsen 2010\n\n495\nInclude: Age <65 with with a history of post op delirium; age>=65, elective TKR or THR.Exclude: Diagnosis of dementia; active alcohol use; history of alcohol abuse; allergy olanzapine; current use of antipsychotic.\n\nThe incidence of delirium was significantly lower in the olanzapine group than in the placebo group (14.3% vs 40.2%, Adjusted OR:0.2, CI: 0.1-0.4, p<0.001). However, delirium lasted longer in the olanzapine group (2.2 [SD\u00031.3] versus 1.6 [SD\u00030.7] days; p=0.02). The severity of delirium was also greater in the olanzapine-treated group than in the placebo group (16.44 [SD: 3.7] vs 14.5 [SD: 2.7]; p=0.02).\nHigh dropout rate, patients stratified by complexity of surgery\n    Fukata 2017\n\n201\nInclude: Patients age >=75 years; elective abdominal surgery under general anesthesia or elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM <20; use of new antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents 2 wks before surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, patients receiving 5 mg haloperidol (n=99) postoperatively, experienced less delirium on postoperative day 1 compared with patients receiving no treatment (n=100), 3% vs 13%, respectively, p=0.017. Adjusting for age, sex, preoperative cognition, and type of surgery, the risk (OR, 95% CI) of developing severe postoperative delirium in patients receiving haloperidol compared with no treatment was 0.31, 0.13-0.66.\n\n    Li 2019\n\n164\nInclude: Patients age >=65; ASA I-III; elective unilateral total hip replacement or total knee replacement.Exclude: Contraindications to spinal surgery (eg, aortic stenosis, coagulopathy, anticoagulant use, spinal cord disease, refusal of spinal anesthesia); severe hepatic or renal insufficiency; stroke or transient ischemic attack in 1 month; difficulty with neuropsychological assessment (<9 yr education or existing mental disorder).\n\nAmong patients undergoing THA or TKA with spinal anesthesia, patients receiving propofol experienced less postoperative cognitive dysfunction at day 7 compared with patients receiving dexmedetomidine and midazolam, 10/55 (18%) vs 22/55 (40%) vs 28/54 (52%), respectively. No differences in cognitive dysfunction were detected between the groups at 1 yr follow-up.\n\n    Xiang 2022\n\n174\nInclude: Age 65-80 years; ASA II-III.Exclude: Dementia; unstable mental status or illness; hx of stroke; hx of gastric ulcer.\n\nCompared with placebo, methylprednisolone greatly reduced the incidence of delirium at 72 hours following surgery (9 [10.7%] vs 20 [23.8%], p = .03, OR = 2.22 [95% CI 1.05–4.59]).\n\n    Glumac 2021\n\n169\nInclude: Age 41-84 yrs.Exclude: Cerebrovascular incidence 3 years prior; mental illness; visual, hearing, or motor impairment; hx of cardiac or carotid surgery; adrenal gland disease; alcohol or drug abuse; MMSE < 26; Beck Depression score > 19; perioperative stroke.\n\nPostoperative cognitive decline 6 days after surgery (RR 0.510; 95% CI: 0.24 to 1.079, p=0.067) and 4 year after study conducted was lower in dexamethasone group compared to placebo (RR 0.456; 95% CI: 0.192 to 1.100, p=0.068).\n\n    Kalisvaart 2005\n\n430\nInclude: Patients age >=70 years; acute or elective hip surgery; at intermediate (1-2 risk factors) or high risk (3-4 risk factors) for postop delirium out of following: 1) visual impairment (worse than 20/70 after correction), 2) APACHE II >=16, 3) MMSE <=24, and 4) index of dehydration (blood urea nitrogen/creatinine ratio >=18).Exclude: Delirium at admission; no risk factors for postop delirium; haloperidol allergy history; cholinesterase inhibitor use; parkinsonism; epilepsy; levodopa treatment; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay >72 h after admission; prolonged QTc interval >460 ms (males) or >470 ms (females).\n\nDelirium incidence was 15.1% (32/212) among patients receiving haloperidol (1.5 mg daily from admission to 3 days postop) and 16.5% (36/218) among patients receiving placebo, (RR, 95% CI: 0.91, 0.59-1.44). Delirium severity (Delirium Rating Scale mean difference, 4.0 [95% CI: 2.0-5.8]) and delirium duration (mean difference in days, 6.4 [95% CI: 4.0-8.0]) were lower in the haloperidol group compared with the placebo group.\n\n    Fukata 2014\n\n121\nInclude: Patients age >=75 years; elective abdominal surgery under general anesthesia; elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM <20; periodic dosing with new or switched antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents within 2 wks of surgery; previous treatment with haloperidol for delirium after surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, 25/59  (42%) patients receiving 2.5 mg haloperidol on days 1-3 postoperatively experienced delirium compared with 20/60 (33%) patients receiving no treatment, [adjusted OR (95% CI): 1.30 (0.54-3.17), p=0.558].\n\n    Tan 2022\n\n99\nInclude: Age >60; undergoing upper GI endoscopy; ASA I-II.Exclude: Clinically significant cardiorespiratory instability; clinically significant renal or hepatic dysfunction; history of drug/alcohol abuse, neurological disease, auditory, or visual disturbances; pre-existing memory or cognitive impairment; and allergy to anesthetics.\n\nThe addition of 0.1 mg/kg of Remimazolam tosilate as an adjunct to opiate sedation not only achieves more stable perioperative hemodynamics, but also achieves acceptable neuropsychiatric function in elderly patients.\n\n    Wang 2012\n\n457\nInclude: Patients age >=65 years; noncardiac surgery admitted to ICU.Exclude: Schizophrenia; epilepsy; parkinsonism; cholinesterase inhibitor use; levodopa treatment; inability to communicate (coma, profound dementia, language barrier); haloperidol or other neuroleptic use during or after anesthesia; neurosurgery; unlikely survival >24 hrs; prolonged corrected QT >=460 for men or >=470 for women at baseline.\n\nAmong patients undergoing non-cardiac surgery, 35/229  (15%) patients receiving 5 mg haloperidol IV over 12 h postoperatively experienced delirium during the first 7 days post-surgery compared with 53/228 (23%) patients receiving no treatment (p=0.031). A difference was not detected in 28-day mortality between the haloperidol group (0.9%) and the control group (2.6%), p=0.175.\n\n    Aizawa 2002\n\n42\nInclude: Age 70-86 yrs.Exclude: Liver cirrhosis; liver dysfunction; respiratory disturbance; metal disorder; visual impairment; emergency surgery.\n\nThe incidence of postoperative delirium, measured using DSM-IV criteria, was (35.0%) in the non delirium prevention protocol group and (5.0%) in the delirium prevention protocol group (p = 0.023).\n\n    \n      Before-After/Time Series\n    \n    Yamasaki 2019\n\n21\nInclude: Patients age >=65 years; hepatectomy.Exclude: Laparoscopic hepatectomy; ICU admission following hepatectomy.\n\nIn patients undergoing hepatectomy, patients receiving omeprazole experienced less postoperative delirium compared with patients receiving famotidine, 3/11 ((27%) vs 9/10 (90%), p<0.01.\n\n    Ushida 2009\n\n122\nInclude: Patients age >50 years; cervical decompression surgery.Exclude: Pre-existence of dementia or other psychological disorder.\n\nPatients undergoing cervical decompression surgery following a change in protocol (reduction in methylprednisolone dose and encouragement of free body movement) experienced lower incidence of postoperative delirium compared with patients prior to protocol changes [3/41 (7%) vs 23/81 (28%), p=0.009].\n\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n1266\nInclude: Age 65-85 years, English fluency.Exclude: Brain or cardiac surgery, no written consent.\n\nPremedication using midazolam was not associated with higher incidence of delirium (23%) on the first postoperative day in older patients undergoing major noncardiac surgery compared to no midozolam (25%; OR = 0.91; 95% CI, 0.65-1.29; p=0.67).\n\n    Bickel 2008\n\n200\nInclude: Age > 60 yrs.Exclude: Dementia; diagnosis of terminal illness.\n\nDelirium occurred in 24.4% of patients who used psychotropic drugs preoperatively.\nDelirium risk factor from a prospective cohort study of patients undergoing hip surgery. The fully adjusted OR for cognitive impairment among patients with delirium in comparison with the controls without delirium amounted to 4.6 (0.9–42.2) after 8 months and rose to 41.2 (4.3–396.2) after 38 months. Among the 41 patients with delirium a significantly higher proportion (36.6%) died than among the 158 without delirium (10.8%), but after adjustment for confounding variables there remained only a nonsignificant tendency toward an increased mortality risk (1.3 at 8 months vs 1.7 at 38 months).\n    Duprey 2022\n\n566\nInclude: Age 70 years or older English speaking (English need not be first language) Scheduled for eligible high-risk surgery: Orthopedic (total hip or knee replacement; lumbar, cervical, or sacral laminectomy)\nVascular (lower extremity arterial bypass surgery; open abdominal aortic aneurysm repair;\nlower extremity amputation)\nGeneral (open or laparoscopic colectomy)\nPlanned general or regional anesthesia Scheduled at least 6 days before surgery to allow adequate time for the baseline assessment Planned admission to the hospital for at least 2 days Living within 40 miles from study hospitals Exclusion criteria\nActive delirium.Exclude: Active delirium Dementia (dementia diagnosis or score <69 or education-adjusted equivalent on baseline 3MS\ncognitive test)\nHospitalization within 3 months before enrollment to minimize risk of recent delirium Terminal condition with life expectancy < 6 months (eg, metastatic cancer, pancreatic cancer,\nor receiving palliative care)\nInability to perform cognitive tests because of legal blindness or severe deafness.\n\n134 (24%) developed delirium during hospitalization. \n\nPreoperative medication associations with delirium: \nbenzodiazepines (RR, 1.44; 95% CI, 0.85–2.44)\nbeta-blocker (RR, 1.38; 95% CI, 0.94–2.05)\nNSAID (RR, 1.12; 95% CI, 0.77–1.62)\nopioid (RR, 1.22; 95% CI, 0.82–1.82) \nstatin (RR, 1.34; 95% CI, 0.92–1.95)\n\nPostoperative medication associations with delirium (before delirium): \nbenzodiazepine (aHR, 3.23; 95% CI, 2.10–4.99)\nantipsychotic (aHR, 1.48; 95% CI, 0.74–2.94) \nopioid (aHR, 0.82; 95% CI, 0.62–1.11) \n\nAntipsychotic use (either presurgery or postsurgery) was associated with a 0.34 point (standard error, 0.16) decrease in general cognitive performance at 1 month through its effect on delirium (P = .03), despite no total effect being observed.\n\n    \n      Retrospective Cohort\n    \n    Jeong 2016\n\n527\nInclude: Age >=65 yrs.Exclude: Refused surgery, did not have cancer.\n\n8.5 % of patients given delirium-inducing medication were diagnosed with postoperative delirium compared to 0.7% of patients without the medication.\n\n    Mangusan 2015\n\n656\nInclude: Not specified.Exclude:  Not specified.\n\nPostoperative delirium occurred in 31% patients who took oral benzodiazepines after cardiac surgery and in 19.8% of patients taking Ketorolac.\n\n    \n      Case-Control\n    \n    Nandi 2014\n\n463\nInclude: Patients undergoing primary or revision total hip or knee arthroplasty under general anesthesia.Exclude: Spinal anesthesia; antipsychotic drug use.\n\nA case-control study of patients undergoing THA or TKA, reported an increased risk of postoperative delirium among patients administered benzodiazepines during hospital stay compared with patients not receiving benzodiazepines [adjusted OR (95% CI): 9.68 (4.30-21.79)].\nOR adjusted for sex, preop alcohol use, and preop depression.\n    Choi 2019\n\n58\nInclude: Patients with postoperative acute lung injury after lung resection surgery for lung cancer.Exclude: Respiratory distress due to respiratory/systemic infection.\n\nIn a case-control study of patients developing acute lung injury after lung resection surgery, patients administered corticosteroids early (within 72 h) experienced less postoperative delirium compared with patients receiving corticosteroids later  (after 72 h), 10/42 (24%) vs 10/16 (63%), p=0.012. Differences were not detected between the groups in complications or length of stay.\nPatients receiving early treatment with corticosteroids had greater improvements in lung injury score (primary outcome) compared with patients receiving later treatment; however, no difference was detected in mechanical ventilation weaning within 7 days (primary outcome)."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Evidence Synthesis",
    "section": "",
    "text": "Working documents not to be cited or referenced.\nThe current protocol can be found here."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "kq5.html",
    "href": "kq5.html",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "",
    "text": "Among [geriatric] patients 65 years or older undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?"
  },
  {
    "objectID": "kq5.html#outcome-importance-rankings",
    "href": "kq5.html#outcome-importance-rankings",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq5.html#causal-model",
    "href": "kq5.html#causal-model",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Causal Model",
    "text": "Causal Model\n Figure 1. Causal model for the relationship between potentially inappropriate medications and outcomes. Potential mediators include anesthetics, other drugs, pain, hypotension, clinical instability, infection, electrolytes, and sleep deprivation.\n\n\n\n\n\n PIM: potentially inappropriate medications."
  },
  {
    "objectID": "kq5.html#included-studies",
    "href": "kq5.html#included-studies",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Included Studies",
    "text": "Included Studies\n Table 2. Number of studies by design. \n\n\n\n\n\n\n\n  \n    \n    \n  \n  \n  \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n27\n    Before-After/Time Series\n2\n    Prospective Cohort\n3\n    Retrospective Cohort\n2\n    Case-Control\n2\n    Total\n36"
  },
  {
    "objectID": "kq5.html#design-centers-country-surgery",
    "href": "kq5.html#design-centers-country-surgery",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Design, centers, country, surgery",
    "text": "Design, centers, country, surgery\n Table 3. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n\n  \n  \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Surgeryb\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    2778\nGlumac 2017\n\n1\n169\nCroatia\nCardiac\n    3250\nRoyse 2017\n\n3\n555\nAustralia\nCardiac\n    4824\nHakim 2012\n\n1\n101\nEgypta\nCardiac\n    7758\nGlumac 2021\n\n1\n169\nCroatia\nCardiac\n    10036\nSauer 2014\n\n1\n737\nNetherlands\nCardiac\n    10075\nOttens 2014\n\n3\n291\nNetherlands\nCardiac\n    10515\nWhitlock 2015\n\n80\n7507\nCanada\nCardiac\n    14006\nMardani 2013\n\n1\n110\nIrana\nCardiac\n    16533\nDieleman 2012\n\n8\n4494\nNetherlands\nCardiac\n    1937\nHollinger 2021\n\n2\n200\nSwitzerland\nCardiac:Gyn:Ortho:Thoracic:Vasc\n    7686\nXiang 2022\n\n1\n174\nChinaa\nGI/Abdominal\n    9157\nTan 2022\n\n1\n99\nChinaa\nGI/Abdominal\n    9620\nAizawa 2002\n\n1\n42\nJapan\nGI/Abdominal\n    7309\nFukata 2017\n\n3\n201\nJapan\nGI/Abdominal:Hepatic:Ortho\n    9196\nWang 2012\n\n2\n457\nChinaa\nGI/Abdominal:Neuro:Ortho:Thoracic\n    8864\nFukata 2014\n\n5\n121\nJapan\nGI/Abdominal:Ortho\n    1117\nMansouri 2019\n\n1\n150\nIrana\nOptho:Other\n    1625\nWang 2020\n\n1\n44\nChinaa\nOralmax\n    742\nLi 2019\n\n1\n164\nChinaa\nOrtho\n    5164\nSultan 2010\n\n1\n222\nEgypta\nOrtho\n    5765\nZhu 2018\n\n1\n178\nChinaa\nOrtho\n    5809\nZhou 2019\n\n1\n180\nChinaa\nOrtho\n    7098\nLarsen 2010\n\n1\n495\nUSA\nOrtho\n    8574\nKalisvaart 2005\n\n1\n430\nNetherlands\nOrtho\n    13888\nŠakić 2015\n\n1\n60\nCroatia\nOrtho\n    1505\nHongyu 2019\n\n1\n90\nChinaa\nThoracic\n    13731\nYu 2017\n\n1\n92\nChinaa\nThoracic\n    \n      Before-After/Time Series\n    \n    10090\nYamasaki 2019\n\n1\n21\nJapan\nGI/Abdominal\n    9464\nUshida 2009\n\n1\n122\nJapan\nOrtho\n    \n      Prospective Cohort\n    \n    7722\nDuprey 2022\n\n2\n566\nUSA\nGI/Abdominal:Ortho:Vasc\n    2338\nBickel 2008\n\n1\n200\nGermany\nOrtho\n    1332\nWang 2021\n\n1\n1266\nTaiwana\nVarious\n    \n      Retrospective Cohort\n    \n    3727\nMangusan 2015\n\n1\n656\nUSA\nCardiac\n    246\nJeong 2016\n\n1\n527\nSouth Korea\nOther\n    \n      Case-Control\n    \n    9279\nNandi 2014\n\n1\n463\nUSA\nOrtho\n    9977\nChoi 2019\n\n1\n58\nSouth Korea\nThoracic\n  \n  \n    \n      GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n  \n  \n    \n      a Non very high Human Development Index country.\n    \n    \n      b Various indicates more than 4 different types of surgery."
  },
  {
    "objectID": "kq5.html#outline",
    "href": "kq5.html#outline",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Outline",
    "text": "Outline\noutline"
  }
]